WHO issued a progress report Towards universal access to diagnosis and treatment of MDR and XDR-TB by 2015 noting “progress is being made, but the response is far from sufficient given the MDR-TB threat facing the world. Two years on from the Beijing declaration – which was endorsed by all 27 high burden countries featured in this report – the commitments by some countries are too slow off the mark or simply stalled.” In relation to the 27 high burden MDR-TB countries, WHO reported:
– Funding: MDR-TB action plans exist in most of the 27 countries. Funding has increased, from $0.1b in 2009, to $0.5 billion in 2011. However, the estimated need in the Global Plan for MDR-TB worldwide in 2011 is $0.9b.
– Labs: Capacity has increased, but is still only adequate in 60% of the countries.
– Treatment: Only one-in-ten MDR-TB patients have access to treatment – and cure rates range widely from 25% to 82%.
– Drugs: The Global Drug Facility has more than doubled the number of finished pharmaceutical products for MDR-TB from 11 in 2008 to 25 today.
– Treatment capacity: If diagnostic capacity increases substantially in the next few months, the availability of second line drugs to treat all those diagnosed will be a challenge.
– TB infection control: In many countries this is still at a planning stage.
– Surveillance: Major progress has been made. By mid 2012, all 27 countries will have representative information on drug resistance.